Page last updated: 2024-08-05 12:50:27
hydroxy polyunsaturated fatty acid
Any polyunsaturated fatty acid carrying one or more hydroxy substituents.
ChEBI ID: 140345
Members (14)
| Member | Definition | Role |
|---|---|---|
| 12-hydroxy-5,8,10-heptadecatrienoic acid | A trienoic fatty acid that consists of heptadeca-5,8,10-trienoic acid bearing an additional 12-hydroxy substituent. | 12-HHTrE |
| 5-oxo-15-hydroxy-6,8,11,13-eicosatetraenoic acid | An icosanoid that is (6E,8Z,11Z,13E)-icosatetraenoic acid substituted at positions 5 and 15 by oxo and hydroxy groups respectively. | (6E,8Z,11Z,13E,15S)-15-hydroxy-5-oxoicosatetraenoic acid |
| 5,12-dihydroxy-6,8,14-eicosatrienoic acid | A leukotriene obtained by formal dehydrogenation of the 10,11-double bond in leukotriene B4. | 10,11-dihydroleukotriene B4 |
| 5s,12r,18r-trihydroxy-6z,8e,10e,14z,16e-eicosapentaenoic acid | A resolvin that is (6Z,8E,10E,14Z,16E)-icosa-6,8,10,14,16-pentaenoic acid which is substituted at positions 5, 12 and 18 by hydroxy groups (the 5S,12R,18R stereoisomer). | resolvin E1 |
| ci 940 | A leptomycin having a (2E,10E,12E,16Z,18E)-double bond configuration as well as an ethyl substituent at position 17. | leptomycin B |
| leukotriene b4 | A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway. | leukotriene B4 |
| leukotriene b5 | A leukotriene composed of (6Z,8E,10E,14Z,17Z)-icosapentaenoic acid carrying (5S)- and (12R)-hydroxy substituents. | leukotriene B5 |
| lipoxin a4 | A C20 hydroxy fatty acid having (5S)-, (6R)- and (15S)-hydroxy groups as well as (7E)- (9E)-, (11Z)- and (13E)-double bonds. | lipoxin A4 |
| minquartynoic acid | A straight-chain, C18 polyunsaturated fatty acid having four conjugated C#C bonds at positions 9, 11, 13 and 15 as well as an (S)-hydroxy group at position 17. | minquartynoic acid |
| resolvin d1 | A resolvin that is docosa-4Z,9E,11E,13Z,15E,19Z-hexaenoic acid which is substituted by hydroxy groups at the 7, 8, and 17 positions (the 7S,8R,17S-stereoisomer). | resolvin D1 |
| resolvin d2 | A member of the class of resolvins that is (4Z,8E,10Z,12E,14E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 7, 16 and 17 (the 7S,16R,17S-stereoisomer). | resolvin D2 |
| resolvin d3 | A member of the class of resolvins that is (5Z,7E,9E,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 11 and 17 (the 4S,11R,17S-stereoisomer). | resolvin D3 |
| resolvin D4 | A member of the class of resolvins that is (6E,8E,10Z,13Z,15E,19Z)-docosahexaenoic acid carrying three hydroxy substituents at positions 4, 5 and 17 (the 4S,5R,17S-stereoisomer). | resolvin D4 |
| resolvin e2 | A member of the class of resolvins that is (6E,8Z,11Z,14Z,16E)-icosapentaenoic acid carrying two hydroxy substituents at positions 5 and 18 (the 5S,18R stereoisomer). | resolvin E2 |
Research
Studies (7,122)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1,905 (26.75) | 18.7374 |
| 1990's | 2,270 (31.87) | 18.2507 |
| 2000's | 1,213 (17.03) | 29.6817 |
| 2010's | 1,328 (18.65) | 24.3611 |
| 2020's | 406 (5.70) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 284 (3.71%) | 5.53% |
| Reviews | 508 (6.64%) | 6.00% |
| Case Studies | 27 (0.35%) | 4.05% |
| Observational | 6 (0.08%) | 0.25% |
| Other | 6,831 (89.22%) | 84.16% |